Inhibitors of human immunodeficiency virus (HIV)–encodedprotease, combined with nucleoside analogues with antiretroviralactivity, cause profound and sustained suppression of viralreplication, reduce morbidity, and prolong life in patientswith HIV infection.1,2,3 Recent guidelines recommend that initialtreatment of all HIV-infected patients include the administrationof an HIV-protease inhibitor.4
The HIV-Encoded Protease
The HIV protease, encoded in the 5' end of the pol gene, isexpressed as part of the gag–pol polyprotein (Figure 1A,Figure 1B, and Figure 1C). This gene encodes a 99-amino-acidprotein. Homodimers of this protein have the aspartyl proteaseactivity that is typical of retroviral . . . [Full Text of this Article]
Mechanism of Action of HIV-Protease Inhibitors
Clinical Pharmacologic Properties
Drug Interactions
Side Effects
Clinical Antiviral Activity
Monotherapy
Combination Therapy
Resistance and Treatment Failure
Pathophysiologic Consequences
Conclusions
Source Information
From the Division of Clinical Pharmacology, Department of Medicine and Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore.
Address reprint requests to Dr. Flexner at Osler 524, Johns Hopkins Hospital, 600 N. Wolfe St., Baltimore, MD 21287-5554.
References
Related Letters:
HIV-Protease Inhibitors
Di Perri G., Del Bravo P., Concia E., Palleja S., Flexner C. W.
Extract |
Full Text
N Engl J Med 1998;
339:773-774, Sep 10, 1998.
Correspondence
This article has been cited by other articles:
Coffinier, C., Hudon, S. E., Lee, R., Farber, E. A., Nobumori, C., Miner, J. H., Andres, D. A., Spielmann, H. P., Hrycyna, C. A., Fong, L. G., Young, S. G.
(2008). A Potent HIV Protease Inhibitor, Darunavir, Does Not Inhibit ZMPSTE24 or Lead to an Accumulation of Farnesyl-prelamin A in Cells. J. Biol. Chem.
283: 9797-9804
[Abstract][Full Text]
Tappouni, H. L., Rublein, J. C., Donovan, B. J., Hollowell, S. B., Tien, H.-C., Min, S. S., Theodore, D., Rezk, N. L., Smith, P. C., Tallman, M. N., Raasch, R. H., Kashuba, A. D. M.
(2008). Effect of omeprazole on the plasma concentrations of indinavir when administered alone and in combination with ritonavir. Am J Health Syst Pharm
65: 422-428
[Abstract][Full Text]
Hadad, N., Levy, R., Schlaeffer, F., Riesenberg, K.
(2007). Direct Effect of Human Immunodeficiency Virus Protease Inhibitors on Neutrophil Function and Apoptosis via Calpain Inhibition. CVI
14: 1515-1521
[Abstract][Full Text]
Laurence, J., Modarresi, R., Wang, X., Yao, Q., Chen, C.
(2007). Modeling Metabolic Effects of the HIV Protease Inhibitor Ritonavir In Vitro. Am. J. Pathol.
171: 1724-1725
[Full Text]
Klei, H. E., Kish, K., Lin, P.-F. M., Guo, Q., Friborg, J., Rose, R. E., Zhang, Y., Goldfarb, V., Langley, D. R., Wittekind, M., Sheriff, S.
(2007). X-Ray Crystal Structures of Human Immunodeficiency Virus Type 1 Protease Mutants Complexed with Atazanavir. J. Virol.
81: 9525-9535
[Abstract][Full Text]
Coffinier, C., Hudon, S. E., Farber, E. A., Chang, S. Y., Hrycyna, C. A., Young, S. G., Fong, L. G.
(2007). From the Cover: HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells. Proc. Natl. Acad. Sci. USA
104: 13432-13437
[Abstract][Full Text]
Doron-Faigenboim, A., Pupko, T.
(2007). A Combined Empirical and Mechanistic Codon Model. Mol Biol Evol
24: 388-397
[Abstract][Full Text]
Zhou, H., Gurley, E. C., Jarujaron, S., Ding, H., Fang, Y., Xu, Z., Pandak, W. M. Jr., Hylemon, P. B.
(2006). HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol.
291: G1071-G1080
[Abstract][Full Text]
Cadranel, J, Garfield, D, Lavole, A, Wislez, M, Milleron, B, Mayaud, C
(2006). Lung cancer in HIV infected patients: facts, questions and challenges.. Thorax
61: 1000-1008
[Abstract][Full Text]
Ford, S. L., Reddy, Y. S., Anderson, M. T., Murray, S. C., Fernandez, P., Stein, D. S., Johnson, M. A.
(2006). Single-dose safety and pharmacokinetics of brecanavir, a novel human immunodeficiency virus protease inhibitor.. Antimicrob. Agents Chemother.
50: 2201-2206
[Abstract][Full Text]
Martin, F., Roth, D. M., Jans, D. A., Pouton, C. W., Partridge, L. J., Monk, P. N., Moseley, G. W.
(2005). Tetraspanins in Viral Infections: a Fundamental Role in Viral Biology?. J. Virol.
79: 10839-10851
[Full Text]
Zhou, H., Pandak, W. M. Jr., Lyall, V., Natarajan, R., Hylemon, P. B.
(2005). HIV Protease Inhibitors Activate the Unfolded Protein Response in Macrophages: Implication for Atherosclerosis and Cardiovascular Disease. Mol. Pharmacol.
68: 690-700
[Abstract][Full Text]
Stanic, A., Schneider, T. K.
(2005). Overview of Antiretroviral Agents in 2005. Journal of Pharmacy Practice
18: 228-246
[Abstract]
Edwards, J. E., Alcorn, J., Savolainen, J., Anderson, B. D., McNamara, P. J.
(2005). Role of P-Glycoprotein in Distribution of Nelfinavir across the Blood-Mammary Tissue Barrier and Blood-Brain Barrier. Antimicrob. Agents Chemother.
49: 1626-1628
[Abstract][Full Text]
Doron-Faigenboim, A., Stern, A., Mayrose, I., Bacharach, E., Pupko, T.
(2005). Selecton: a server for detecting evolutionary forces at a single amino-acid site. Bioinformatics
21: 2101-2103
[Abstract][Full Text]
Toffoli, G., Corona, G., Cattarossi, G., Boiocchi, M., Di Gennaro, G., Tirelli, U., Vaccher, E.
(2004). Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol
15: 1805-1809
[Abstract][Full Text]
Winnock, M., Salmon-Ceron, D., Dabis, F., Chene, G.
(2004). Interaction between HIV-1 and HCV infections: towards a new entity?. J Antimicrob Chemother
53: 936-946
[Abstract][Full Text]
Rufo, P. A., Lin, P. W., Andrade, A., Jiang, L., Rameh, L., Flexner, C., Alper, S. L., Lencer, W. I.
(2004). Diarrhea-associated HIV-1 APIs potentiate muscarinic activation of Cl- secretion by T84 cells via prolongation of cytosolic Ca2+ signaling. Am. J. Physiol. Cell Physiol.
286: C998-C1008
[Abstract][Full Text]
Hadri, K. E., Glorian, M., Monsempes, C., Dieudonne, M.-N., Pecquery, R., Giudicelli, Y., Andreani, M., Dugail, I., Feve, B.
(2004). In Vitro Suppression of the Lipogenic Pathway by the Nonnucleoside Reverse Transcriptase Inhibitor Efavirenz in 3T3 and Human Preadipocytes or Adipocytes. J. Biol. Chem.
279: 15130-15141
[Abstract][Full Text]
Shelton, M. J., Cloen, D., DiFrancesco, R., Berenson, C. S., Esch, A., de Caprariis, P. J., Palic, B., Schur, J. L., Bugge, C. J. L., Ljungqvist, A., Espinosa, O., Hewitt, R. G.
(2004). The Effects of Once-Daily Saquinavir/Minidose Ritonavir on the Pharmacokinetics of Methadone. J Clin Pharmacol
44: 293-304
[Abstract][Full Text]
Schonder, K. S, Shullo, M. A, Okusanya, O.
(2003). Tacrolimus and Lopinavir/Ritonavir Interaction in Liver Transplantation. The Annals of Pharmacotherapy
37: 1793-1796
[Abstract][Full Text]
Martinez, E., Arnaiz, J. A., Podzamczer, D., Dalmau, D., Ribera, E., Domingo, P., Knobel, H., Riera, M., Pedrol, E., Force, L., Llibre, J. M., Segura, F., Richart, C., Cortes, C., Javaloyas, M., Aranda, M., Cruceta, A., de Lazzari, E., Gatell, J. M., the Nevirapine, Efavirenz, and Abacavir (NEFA) Stu,
(2003). Substitution of Nevirapine, Efavirenz, or Abacavir for Protease Inhibitors in Patients with Human Immunodeficiency Virus Infection. NEJM
349: 1036-1046
[Abstract][Full Text]
Ford, J., Meaden, E. R., Hoggard, P. G., Dalton, M., Newton, P., Williams, I., Khoo, S. H., Back, D. J.
(2003). Effect of protease inhibitor-containing regimens on lymphocyte multidrug resistance transporter expression. J Antimicrob Chemother
52: 354-358
[Abstract][Full Text]
Martinez-Picado, J., Negredo, E., Ruiz, L., Shintani, A., Fumaz, C. R., Zala, C., Domingo, P., Vilaro, J., Llibre, J. M., Viciana, P., Hertogs, K., Boucher, C., D'Aquila, R. T., Clotet, B., the SWATCH Study Team*,
(2003). Alternation of Antiretroviral Drug Regimens for HIV Infection: A Randomized, Controlled Trial. ANN INTERN MED
139: 81-89
[Abstract][Full Text]
Mikhail, N., Cope, D.
(2003). The Use of Statins in Conjunction With Protease Inhibitors and in Renal Insufficiency. Arch Intern Med
163: 1615-1616
[Full Text]
Lin, Y.-C., Beck, Z., Morris, G. M., Olson, A. J., Elder, J. H.
(2003). Structural Basis for Distinctions between Substrate and Inhibitor Specificities for Feline Immunodeficiency Virus and Human Immunodeficiency Virus Proteases. J. Virol.
77: 6589-6600
[Abstract][Full Text]
Calabrese, L. H., Albrecht, M., Young, J., McCarthy, P., Haug, M., Jarcho, J., Zackin, R.
(2003). Successful Cardiac Transplantation in an HIV-1-Infected Patient with Advanced Disease. NEJM
348: 2323-2328
[Full Text]
Woerle, H. J., Mariuz, P. R., Meyer, C., Reichman, R. C., Popa, E. M., Dostou, J. M., Welle, S. L., Gerich, J. E.
(2003). Mechanisms for the Deterioration in Glucose Tolerance Associated With HIV Protease Inhibitor Regimens. Diabetes
52: 918-925
[Abstract][Full Text]
Prabu-Jeyabalan, M., Nalivaika, E. A., King, N. M., Schiffer, C. A.
(2002). Viability of a Drug-Resistant Human Immunodeficiency Virus Type 1 Protease Variant: Structural Insights for Better Antiviral Therapy. J. Virol.
77: 1306-1315
[Abstract][Full Text]
Williams, G. C., Liu, A., Knipp, G., Sinko, P. J.
(2002). Direct Evidence that Saquinavir Is Transported by Multidrug Resistance-Associated Protein (MRP1) and Canalicular Multispecific Organic Anion Transporter (MRP2). Antimicrob. Agents Chemother.
46: 3456-3462
[Abstract][Full Text]
Chen, D., Misra, A., Garg, A.
(2002). Lipodystrophy in Human Immunodeficiency Virus-Infected Patients. J. Clin. Endocrinol. Metab.
87: 4845-4856
[Abstract][Full Text]
Zhong, D.-s., Lu, X.-h., Conklin, B. S., Lin, P. H., Lumsden, A. B., Yao, Q., Chen, C.
(2002). HIV Protease Inhibitor Ritonavir Induces Cytotoxicity of Human Endothelial Cells. Arterioscler. Thromb. Vasc. Bio.
22: 1560-1566
[Abstract][Full Text]
Pajonk, F., Himmelsbach, J., Riess, K., Sommer, A., McBride, W. H.
(2002). The Human Immunodeficiency Virus (HIV)-1 Protease Inhibitor Saquinavir Inhibits Proteasome Function and Causes Apoptosis and Radiosensitization in Non-HIV-associated Human Cancer Cells. Cancer Res.
62: 5230-5235
[Abstract][Full Text]
Trabattoni, D., Lo Caputo, S., Biasin, M., Seminari, E., Di Pietro, M., Ravasi, G., Mazzotta, F., Maserati, R., Clerici, M.
(2002). Modulation of Human Immunodeficiency Virus (HIV)-Specific Immune Response by Using Efavirenz, Nelfinavir, and Stavudine in a Rescue Therapy Regimen for HIV-Infected, Drug-Experienced Patients. CVI
9: 1114-1118
[Abstract][Full Text]
Hammer, S. M., Vaida, F., Bennett, K. K., Holohan, M. K., Sheiner, L., Eron, J. J., Wheat, L. J., Mitsuyasu, R. T., Gulick, R. M., Valentine, F. T., Aberg, J. A., Rogers, M. D., Karol, C. N., Saah, A. J., Lewis, R. H., Bessen, L. J., Brosgart, C., DeGruttola, V., Mellors, J. W., for the AIDS Clinical Trials Group 398 Study Team,
(2002). Dual vs Single Protease Inhibitor Therapy Following Antiretroviral Treatment Failure: A Randomized Trial. JAMA
288: 169-180
[Abstract][Full Text]
Dieleman, J. P., Sturkenboom, M. C. J. M., Jambroes, M., Gyssens, I. C., Weverling, G.-J., ten Veen, J. H., Schrey, G., Reiss, P., Stricker, B. H. Ch., for the ATHENA Study Group,
(2002). Risk Factors for Urological Symptoms in a Cohort of Users of the HIV Protease Inhibitor Indinavir Sulfate: The ATHENA Cohort. Arch Intern Med
162: 1493-1501
[Abstract][Full Text]
Blusch, J. H., Seelmeir, S., von der Helm, K.
(2002). Molecular and Enzymatic Characterization of the Porcine Endogenous Retrovirus Protease. J. Virol.
76: 7913-7917
[Abstract][Full Text]
Walmsley, S., Bernstein, B., King, M., Arribas, J., Beall, G., Ruane, P., Johnson, M., Johnson, D., Lalonde, R., Japour, A., Brun, S., Sun, E., the M98-863 Study Team,
(2002). Lopinavir-Ritonavir versus Nelfinavir for the Initial Treatment of HIV Infection. NEJM
346: 2039-2046
[Abstract][Full Text]
Levine, A. M.
(2002). Evaluation and Management of HIV-Infected Women. ANN INTERN MED
136: 228-242
[Abstract][Full Text]
Krishnan, A., Molina, A., Zaia, J., Nademanee, A., Kogut, N., Rosenthal, J., Woo, D., Forman, S. J.
(2001). Autologous stem cell transplantation for HIV-associated lymphoma. Blood
98: 3857-3859
[Abstract][Full Text]
Phenix, B. N., Lum, J. J., Nie, Z., Sanchez-Dardon, J., Badley, A. D.
(2001). Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood
98: 1078-1085
[Abstract][Full Text]
Caron, M., Auclair, M., Vigouroux, C., Glorian, M., Forest, C., Capeau, J.
(2001). The HIV Protease Inhibitor Indinavir Impairs Sterol Regulatory Element-Binding Protein-1 Intranuclear Localization, Inhibits Preadipocyte Differentiation, and Induces Insulin Resistance. Diabetes
50: 1378-1388
[Abstract][Full Text]
Rudich, A., Vanounou, S., Riesenberg, K., Porat, M., Tirosh, A., Harman-Boehm, I., Greenberg, A. S., Schlaeffer, F., Bashan, N.
(2001). The HIV Protease Inhibitor Nelfinavir Induces Insulin Resistance and Increases Basal Lipolysis in 3T3-L1 Adipocytes. Diabetes
50: 1425-1431
[Abstract][Full Text]
Thurnher, M. M., Donovan Post, M. J., Rieger, A., Kleibl-Popov, C., Loewe, C., Schindler, E.
(2001). Initial and Follow-up MR Imaging Findings in AIDS-Related Progressive Multifocal Leukoencephalopathy Treated with Highly Active Antiretroviral Therapy. Am. J. Neuroradiol.
22: 977-984
[Abstract][Full Text]
Zhang, K. E., Wu, E., Patick, A. K., Kerr, B., Zorbas, M., Lankford, A., Kobayashi, T., Maeda, Y., Shetty, B., Webber, S.
(2001). Circulating Metabolites of the Human Immunodeficiency Virus Protease Inhibitor Nelfinavir in Humans: Structural Identification, Levels in Plasma, and Antiviral Activities. Antimicrob. Agents Chemother.
45: 1086-1093
[Abstract][Full Text]
Izzedine, H., Launay-Vacher, V., Deray, G.
(2001). Pharmacokinetics of ritonavir and nevirapine in peritoneal dialysis. Nephrol Dial Transplant
16: 643-643
[Full Text]
Polk, R. E., Brophy, D. F., Israel, D. S., Patron, R., Sadler, B. M., Chittick, G. E., Symonds, W. T., Lou, Y., Kristoff, D., Stein, D. S.
(2001). Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males. Antimicrob. Agents Chemother.
45: 502-508
[Abstract][Full Text]
Sadler, B. M., Gillotin, C., Lou, Y., Stein, D. S.
(2001). Pharmacokinetic and Pharmacodynamic Study of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir after Multiple Oral Dosing. Antimicrob. Agents Chemother.
45: 30-37
[Abstract][Full Text]
Ikezoe, T., Daar, E. S., Hisatake, J.-i., Taguchi, H., Koeffler, H. P.
(2000). HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood
96: 3553-3559
[Abstract][Full Text]
Barcellini, W., Colombo, G., La Maestra, L., Clerici, G., Garofalo, L., Brini, A. T., Lipton, J. M., Catania, A.
(2000). {alpha}-Melanocyte-stimulating hormone peptides inhibit HIV-1 expression in chronically infected promonocytic U1 cells and in acutely infected monocytes. J. Leukoc. Biol.
68: 693-699
[Abstract][Full Text]
Kilby, J. M., Sfakianos, G., Gizzi, N., Siemon-Hryczyk, P., Ehrensing, E., Oo, C., Buss, N., Saag, M. S.
(2000). Safety and Pharmacokinetics of Once-Daily Regimens of Soft-Gel Capsule Saquinavir plus Minidose Ritonavir in Human Immunodeficiency Virus-Negative Adults. Antimicrob. Agents Chemother.
44: 2672-2678
[Abstract][Full Text]
Derouin, F., Santillana-Hayat, M.
(2000). Anti-Toxoplasma Activities of Antiretroviral Drugs and Interactions with Pyrimethamine and Sulfadiazine In Vitro. Antimicrob. Agents Chemother.
44: 2575-2577
[Abstract][Full Text]
Dybul, M., Mercier, G., Belson, M., Hallahan, C. W., Liu, S., Perry, C., Herpin, B., Ehler, L., Davey, R. T., Metcalf, J. A., Mican, J. M., Seder, R. A., Fauci, A. S.
(2000). CD40 Ligand Trimer and IL-12 Enhance Peripheral Blood Mononuclear Cells and CD4+ T Cell Proliferation and Production of IFN-{gamma} in Response to p24 Antigen in HIV-Infected Individuals: Potential Contribution of Anergy to HIV-Specific Unresponsiveness. J. Immunol.
165: 1685-1691
[Abstract][Full Text]
Schwarcz, S. K., Hsu, L. C., Vittinghoff, E., Katz, M. H.
(2000). Impact of Protease Inhibitors and Other Antiretroviral Treatments on Acquired Immunodeficiency Syndrome Survival in San Francisco, California, 1987-1996. Am J Epidemiol
152: 178-185
[Abstract][Full Text]
Lin, Y.-C., Beck, Z., Lee, T., Le, V.-D., Morris, G. M., Olson, A. J., Wong, C.-H., Elder, J. H.
(2000). Alteration of Substrate and Inhibitor Specificity of Feline Immunodeficiency Virus Protease. J. Virol.
74: 4710-4720
[Abstract][Full Text]
Speck, R. R., Flexner, C., Tian, C.-J., Yu, X.-F.
(2000). Comparison of Human Immunodeficiency Virus Type 1 Pr55Gag and Pr160Gag-Pol Processing Intermediates That Accumulate in Primary and Transformed Cells Treated with Peptidic and Nonpeptidic Protease Inhibitors. Antimicrob. Agents Chemother.
44: 1397-1403
[Abstract][Full Text]
Brophy, D. F., Israel, D. S., Pastor, A., Gillotin, C., Chittick, G. E., Symonds, W. T., Lou, Y., Sadler, B. M., Polk, R. E.
(2000). Pharmacokinetic Interaction between Amprenavir and Clarithromycin in Healthy Male Volunteers. Antimicrob. Agents Chemother.
44: 978-984
[Abstract][Full Text]
Ziebuhr, J., Snijder, E. J., Gorbalenya, A. E.
(2000). Virus-encoded proteinases and proteolytic processing in the Nidovirales. J. Gen. Virol.
81: 853-879
[Full Text]
Leyssen, P., De Clercq, E., Neyts, J.
(2000). Perspectives for the Treatment of Infections with Flaviviridae. Clin. Microbiol. Rev.
13: 67-82
[Abstract][Full Text]
Staszewski, S., Morales-Ramirez, J., Tashima, K. T., Rachlis, A., Skiest, D., Stanford, J., Stryker, R., Johnson, P., Labriola, D. F., Farina, D., Manion, D. J., Ruiz, N. M., The Study 006 Team,
(1999). Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults. NEJM
341: 1865-1873
[Abstract][Full Text]
Zolopa, A. R., Shafer, R. W., Warford, A., Montoya, J. G., Hsu, P., Katzenstein, D., Merigan, T. C., Efron, B.
(1999). HIV-1 Genotypic Resistance Patterns Predict Response to saquinavir-ritonavir Therapy in Patients in Whom Previous Protease Inhibitor Therapy Had Failed. ANN INTERN MED
131: 813-821
[Abstract][Full Text]
Harrington, R. D., Woodward, J. A., Hooton, T. M., Horn, J. R.
(1999). Life-Threatening Interactions Between HIV-1 Protease Inhibitors and the Illicit Drugs MDMA and {gamma}-Hydroxybutyrate. Arch Intern Med
159: 2221-2224
[Abstract][Full Text]
McCoig, C., Van Dyke, G., Chou, C.-S., Picker, L. J., Ramilo, O., Vitetta, E. S.
(1999). An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro. Proc. Natl. Acad. Sci. USA
96: 11482-11485
[Abstract][Full Text]
Bossi, P., Mouroux, M., Yvon, A., Bricaire, F., Agut, H., Huraux, J.-M., Katlama, C., Calvez, V.
(1999). Polymorphism of the Human Immunodeficiency Virus Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to a Protease Inhibitor. J. Clin. Microbiol.
37: 2910-2912
[Abstract][Full Text]
Moyer, T. P., Temesgen, Z., Enger, R., Estes, L., Charlson, J., Oliver, L., Wright, A.
(1999). Drug Monitoring of Antiretroviral Therapy for HIV-1 Infection: Method Validation and Results of a Pilot Study. Clin. Chem.
45: 1465-1476
[Abstract][Full Text]
Louis, J. M., Wondrak, E. M., Kimmel, A. R., Wingfield, P. T., Nashed, N. T.
(1999). Proteolytic Processing of HIV-1 Protease Precursor, Kinetics and Mechanism. J. Biol. Chem.
274: 23437-23442
[Abstract][Full Text]
Valdez, H., Lederman, M. M., Woolley, I., Walker, C. J., Vernon, L. T., Hise, A., Gripshover, B. M.
(1999). Human Immunodeficiency Virus 1 Protease Inhibitors in Clinical Practice: Predictors of Virological Outcome. Arch Intern Med
159: 1771-1776
[Abstract][Full Text]
Sloand, E. M., Kumar, P. N., Kim, S., Chaudhuri, A., Weichold, F. F., Young, N. S.
(1999). Human Immunodeficiency Virus Type 1 Protease Inhibitor Modulates Activation of Peripheral Blood CD4+ T Cells and Decreases Their Susceptibility to Apoptosis In Vitro and In Vivo. Blood
94: 1021-1027
[Abstract][Full Text]
Lucas, G. M., Chaisson, R. E., Moore, R. D.
(1999). Highly Active Antiretroviral Therapy in a Large Urban Clinic: Risk Factors for Virologic Failure and Adverse Drug Reactions. ANN INTERN MED
131: 81-87
[Abstract][Full Text]
Sadler, B. M., Hanson, C. D., Chittick, G. E., Symonds, W. T., Roskell, N. S.
(1999). Safety and Pharmacokinetics of Amprenavir (141W94), a Human Immunodeficiency Virus (HIV) Type 1 Protease Inhibitor, following Oral Administration of Single Doses to HIV-Infected Adults. Antimicrob. Agents Chemother.
43: 1686-1692
[Abstract][Full Text]
Lee, E. C. C., Walmsley, S., Fantus, I. G.
(1999). New-onset diabetes mellitus associated with protease inhibitor therapy in an HIV-positive patient: case report and review. CMAJ
161: 161-164
[Full Text]
Corcoran, C., Grinspoon, S.
(1999). Treatments for Wasting in Patients with the Acquired Immunodeficiency Syndrome. NEJM
340: 1740-1750
[Full Text]
Engelson, E. S, Kotler, D. P, Tan, Y., Agin, D., Wang, J., Pierson, R. N Jr, Heymsfield, S. B
(1999). Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging. Am. J. Clin. Nutr.
69: 1162-1169
[Abstract][Full Text]
Goldie, S. J., Kuntz, K. M., Weinstein, M. C., Freedberg, K. A., Welton, M. L., Palefsky, J. M.
(1999). The Clinical Effectiveness and Cost-effectiveness of Screening for Anal Squamous Intraepithelial Lesions in Homosexual and Bisexual HIV-Positive Men. JAMA
281: 1822-1829
[Abstract][Full Text]
Louis, J. M., Oroszlan, S., Tozser, J.
(1999). Stabilization from Autoproteolysis and Kinetic Characterization of the Human T-cell Leukemia Virus Type 1 Proteinase. J. Biol. Chem.
274: 6660-6666
[Abstract][Full Text]
Goldie, S. J., Weinstein, M. C., Kuntz, K. M., Freedberg, K. A.
(1999). The Costs, Clinical Benefits, and Cost-Effectiveness of Screening for Cervical Cancer in HIV-Infected Women. ANN INTERN MED
130: 97-107
[Abstract][Full Text]
OLIVÉ, A., SALAVERT, A., MANRÍQUEZ, M., CLOTET, B., MORAGAS, A.
(1998). Ultrasound guided injection of plantar fasciitis.. Ann Rheum Dis
57: 749-750
[Full Text]
Costner, M., Cockerell, C. J.
(1998). The Changing Spectrum of the Cutaneous Manifestations of HIV Disease. Arch Dermatol
134: 1290-1292
[Full Text]
Di Perri, G., Del Bravo, P., Concia, E., Palleja, S., Flexner, C. W.
(1998). HIV-Protease Inhibitors. NEJM
339: 773-774
[Full Text]
Celentano, D. D., Vlahov, D., Cohn, S., Shadle, V. M., Obasanjo, O., Moore, R. D.
(1998). Self-reported Antiretroviral Therapy in Injection Drug Users. JAMA
280: 544-546
[Abstract][Full Text]
Murata, H., Hruz, P. W., Mueckler, M.
(2000). The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy. J. Biol. Chem.
275: 20251-20254
[Abstract][Full Text]
Dowell, P., Flexner, C., Kwiterovich, P. O., Lane, M. D.
(2000). Suppression of Preadipocyte Differentiation and Promotion of Adipocyte Death by HIV Protease Inhibitors. J. Biol. Chem.
275: 41325-41332
[Abstract][Full Text]
Riddle, T. M., Kuhel, D. G., Woollett, L. A., Fichtenbaum, C. J., Hui, D. Y.
(2001). HIV Protease Inhibitor Induces Fatty Acid and Sterol Biosynthesis in Liver and Adipose Tissues Due to the Accumulation of Activated Sterol Regulatory Element-binding Proteins in the Nucleus. J. Biol. Chem.
276: 37514-37519
[Abstract][Full Text]
Previous
